Infant nutrition company Biotime is just the latest of such companies within China to modify its business practices following the announcement of an antirust investigation into the sector by Chinese authorities. The nation’s National Reform and Development Commission launched a probe into various makers of infant formula for suspicion of price-fixing. Biostime announced Tuesday plans to revise contracts with its distributors, according to reports. The case is particular, however, as reports say the price-fixing probe focuses on foreign companies in the market; Biostime is a domestic company. The company’s wholly-owned Chinese subsidiary is currently under investigation by the NDRC.
Full Content: Middle East North Africa Financial Network
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Colorado Senate Rejects Bill Barring Rent-Setting Algorithms
May 2, 2024 by
CPI
Bayer Faces US Antitrust Suit Over Pet Meds Competition
May 2, 2024 by
CPI
Landmark Monopoly Trial Between DOJ and Google Wraps Up
May 2, 2024 by
CPI
Lawmaker Probes FTC and EU’s Role in Amazon’s Failed iRobot Acquisition
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI